NeOnc Technologies prices $15M registered direct offering
NeOnc Technologies, a biopharmaceutical company focused on CNS cancer therapies, announced plans to raise approximately $15 million through a registered direct offering of 3.57 million shares or warrants. The offering, priced at $4.20 per share and $0.0001 per pre-funded warrant, is expected to close by Thursday, contingent on customary closing conditions.
Roth Capital Partners and A.G.P./Alliance Global Partners are the co-placement agents for the transaction. NeOnc's lead therapies, NEO100 and NEO212, are in Phase II clinical trials with FDA Fast-Track and Investigational New Drug status. The company also holds a patent portfolio that extends to 2038, covering its oncological and neurological product candidates.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
